Patents by Inventor Paul Calabresi

Paul Calabresi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
    Patent number: 5478804
    Abstract: Conjugates comprising bFGF or other FGF polypeptides and a cytotoxic agent are prepared. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, which is attached to bFGF through a chemical bond, or the composition can be prepared as a recombinant DNA chimera. The conjugates are used to specifically target cells, in vivo and in vitro, which express FGF receptors. The cytotoxicity of the conjugates is proportional to the number of receptors expressed by a cell type. The conjugate is useful to effectively treat mammals, and in particular human patients, afflicted with tumorigenic conditions, such as human melanomas, human ovarian carcinomas, teratocarcinomas and neuroblastomas, and other FGF-mediated tumors caused by a proliferation of cells which express FGF receptors.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: December 26, 1995
    Assignees: The Salk Institute for Biological Studies, Roger Williams General Hospital
    Inventors: Paul Calabresi, Julie G. Beitz, Jeffrey W. Clark, A. Raymond Frackelton, Jr., Douglas A. Lappi, Andrew J. Baird
  • Drug combinations containing AZT
    Patent number: 5116823
    Abstract: Combinations of 3'-azido-3'-deoxythymidine (AZT) with 5-fluorouracil (FUra) or its precursor 5-fluoro-2'-deoxyuridine (FUDR) or methoxtrexate (MTX) exhibit increased cytotoxicity and increased therapeutic index in treatment of carcinomas.
    Type: Grant
    Filed: February 27, 1990
    Date of Patent: May 26, 1992
    Assignee: Roger Williams General Hospital
    Inventors: Paul Calabresi, James W. Darnowski
  • Reduction of the severity of 3'-azido-3'-deoxythymidine-induced anemia using a combination of benzylacyclouridine and dipyridamole
    Patent number: 4950466
    Abstract: The invention is directed to a method of inhibiting anemia caused by the administration of AZT to a patient which comprises administering to said patient an effective anemia-inhibiting amount of a combination of dipyridamole and 5-benzylacyclouridine. The invention is further directed to a pharmaceutical composition comprising as the active pharmaceutical agent a combination of dipyridamole and 5-benzylacyclouridine in association with a pharmaceutically acceptable carrier or diluent.
    Type: Grant
    Filed: June 22, 1988
    Date of Patent: August 21, 1990
    Inventors: Paul Calabresi, James W. Darnowski, Michael C. Wiemann
  • Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
    Patent number: 4874602
    Abstract: A method of reducing anemia caused by the administration of 3'-azido-3'-deoxythymidine to an animal which comprises treating said animal with a compound which inhibits the enzyme uridine phosphorylase in order to increase cellular uridine levels is disclosed. A particularly-effective compound is 5-benzylacyclouridine.
    Type: Grant
    Filed: February 22, 1988
    Date of Patent: October 17, 1989
    Inventors: Paul Calabresi, Michael C. Wiemann, Ming Y. W. Chu
  • Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
    Patent number: 4613604
    Abstract: A compound of the Formula (I): ##STR1## where X is a benzyl group or a benzyloxybenzyl group and pharmaceutical preparations containing the same.
    Type: Grant
    Filed: July 31, 1985
    Date of Patent: September 23, 1986
    Assignee: Brown University Research Foundation
    Inventors: Shih H. Chu, Paul Calabresi, Ming Y. W. Chu, Mahmoud H. el Kouni, Fardos N. M. Naguib, Sungman Cha